Founded in 2008, S1 Biopharma is developing first-in-class drugs for the treatment of sexual dysfunction in both women and men. The company’s non-hormonal therapies work uniquely by restoring the natural balance of neurotransmitters in the brain.

Female sexual dysfunction (FSD) affects 22% of women worldwide. Hypoactive sexual desire disorder (HSDD), or low sexual desire, is the most common form of FSD among women and is believed to be almost as prevalent in men. Despite the high distress and quality of life issues caused by sexual dysfunction, there has been very little progress in the development of safe, effective and validated treatments. S1 Biopharma is aiming to change the treatment landscape by developing drugs that treat several types of sexual dysfunction. Each of the company’s four product candidates in development has blockbuster potential.

Driving these development efforts is a management team with a singular passion for tackling significant, unmet medical needs. Each executive brings decades of industry experience to S1 Biopharma, including expertise related to the treatment of sexual disorders. Complementing the company’s leadership is a medical advisory board comprised of renowned academic and industry experts.

Our mission is to bring first-in-class treatments to the millions of women and men whose lives are disrupted because of sexual function disorders. Since our company’s inception, we have been committed to innovation, integrity, the use of the highest quality science and a deep understanding of the biology underlying these disorders to develop effective treatments with safety as a priority.